（000710）")成立于2010年，15年来，一直致力于基因检测技术向临床应用的全面转化，目前已经有超 2000家医疗机构使用贝瑞基因的基因测序整体解决方案。 近日，《证券日报》记者走进贝瑞基因，与公司董事长高扬共同探讨在AI赋能医疗行业的当下，基因 检测行业如何发展创新；在行业竞争格局日益激烈的情况下，公司如何破局突围。 持续发力人工智能 作为个性化医疗的重要基石，基因检测行业处于飞速发展阶段，政策支持、技术突破和市场需求等共同 推动行业规模持续扩大。 作为A股基因检测概念第一股，成都市贝瑞和康基因技术股份有限公司(以下简称"贝瑞基因 数据安全是人工智能落地应用绕不开的话题。医疗数据涉及个人隐私，如何在利用数据提升医疗服务的 同时，确保数据安全与患者隐私，是当前AI医疗发展面临的重要挑战之一。由此，如何对临床数据进 行高质量标注及算法调优能力，将成为企业的重要竞争力。 "公司在清洗内部积累的数据时，已经进行了整体的梳理工作以及非常有效的信息标注工作。"高扬说。 科学技术不断迭代革新，个性化医疗时代正在崛起。 人工智能技术迅猛发展，"AI+"成为当下市场热点。世界经济论坛发布的报告预计，2024年到2032 ...

最新一期业绩显示，2024年三季报，公司实现营业收入8.23亿元，同比-4.96%；净利润1038.55万元，同 比107.70%，销售毛利率50.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21贝瑞基因-15.89-10.482.3944.79亿行业平均 43.4948.264.72101.42亿行业中值29.2629.262.3044.79亿1天益医疗-2674.15-2674.151.6819.89亿2硕世生 物-1783.03-1783.031.1236.84亿3诺唯赞-537.02-537.022.4697.17亿4澳华内镜-511.00256.294.0953.85亿5博 晖创新-342.22-210.703.7752.53亿6康泰医学-260.3130.542.6650.63亿7华大基因-194.94213.242.02198.10亿 8奥精医疗-109.68-109.681.4019.87亿9睿昂基因-70.97-70.971.2311.19亿10热景生物-62.69-62.693.45112.36 亿11华大智造-52.66-52.663.95315.51亿 来源：金融界 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

证券代码：000710 证券简称：贝瑞基因 成都市贝瑞和康基因技术股份有限公司 投资者关系活动记录表 编号：2025-003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | ☑其他 （电话交流会） | | | 参与单位名称 | 民生证券、中信建投、国盛证券、东北证券、国联民生证券、国 | | | | 泰海通证券、东方财富证券、华金证券、中信证券、中银国际、 | | | | 信达证券、德邦证券、湘财证券、上海证券、兴业证券、国信证 | | | | 券、华源证券、方正证券、华金证券、浙商证券、中邮证券、东 | | | | 吴证券、首创证券、中泰证券、长城基金、上海阜盈投资、青榕 | | | | 资产、观富(北京)资产、北京九州鑫汇投资基金、上海禧弘私募 | | | | 基金、耕霁(上海)投资、深圳中天汇富基金、申银万国、上海匀 | | | | 升投资、上海易正朗投资、上海益和源资产、上海健顺投资、珠 | | | | 海尚石投资、APC ...

Regulatory Developments - The National Medical Products Administration reported four cases of illegal online sales of medical devices, emphasizing a "zero tolerance" regulatory attitude to ensure safety in medical device usage [2] - Companies involved include Jiangyin Tianyu Medical Device Co., Yiwu Shenghe Medical Device Co., Shanghai Yile Warehouse Medical Device Co., and Hefei Baohua Design Studio, all of which failed to comply with regulatory requirements [2] Industry Advancements - Hangzhou is accelerating the development of medical artificial intelligence applications, aiming to establish a national AI (medical) application pilot base and create intelligent medical entities focused on various health management areas [3] - The city plans to build digital health innovation laboratories to advance key technologies in medical AI [3] Company Announcements - Leksin Medical received a medical device registration certificate for its wrist-type electronic blood pressure monitor from the Guangdong Provincial Drug Administration [5] - David Medical's wholly-owned subsidiary, Ningbo Yongxing Medical Instruments Co., obtained a medical device registration certificate for a linear cutting stapler used in various surgical procedures [6] - Warner Pharmaceuticals announced the approval of its drug registration certificate for the injection of methoxamine hydrochloride, used for treating acute hypotension during spinal anesthesia [7] Financial Reports - Guobang Pharmaceutical reported a revenue of 1.44 billion yuan for Q1 2025, a year-on-year increase of 7.57%, with a net profit of 215 million yuan, up 8.17% [9] - Johnson & Johnson's Q1 sales reached 21.89 billion dollars, with an annual sales forecast of 91 to 91.8 billion dollars and adjusted earnings per share projected between 10.50 and 10.70 dollars [10] Market Movements - In Hong Kong, InnoCare's stock surged by 130% on its first trading day [12] - Darentang announced plans to transfer a 12% stake in China-US Tianjin Schering Pharmaceutical Co., with estimated investment income of approximately 1.54 billion yuan from the transaction [13] - Nanjing Noling Biotechnology completed a C-round financing of several hundred million yuan, led by Dingxin Capital [14] Collaborative Initiatives - Berry Genomics' subsidiary signed a project cooperation framework agreement with Beijing Children's Hospital to promote clinical transformation and commercialization of research outcomes related to newborn screening technologies [16] - Bangyan Technology plans to officially launch its AI Agent product this year, aimed at assisting digital transformation in the healthcare sector [17] Personnel Changes - Bell Bio's financial officer, Zhao Baozhen, resigned for personal reasons but will continue to serve as the board secretary [19]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-012 成都市贝瑞和康基因技术股份有限公司 关于全资子公司与首都医科大学附属北京儿童医院 鉴于甲乙双方于2022年11月共同申报了由北京市科学技术委员会、中关村科技园区 管理委员会委托的"首都临床特色诊疗技术研究及转化应用"项目"新生儿功能性出生 缺陷的早筛早诊关键技术研究及产品研发"课题（课题号：Z221100007422017），并承 担项目成果转化的任务。双方为推动项目成果的临床转化和商业化应用，本着平等互 利、优势互补、协同发展的原则，经友好协商，达成合作框架协议。 签署《项目成果转化合作框架协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次签署的《项目成果转化合作框架协议》相关约定付诸实施和实施过程中均 存在变动的可能性，具体的实施内容和进度将根据双方后续工作进一步落实和推进，敬 请广大投资者注意投资风险。 2、本次签署的《项目成果转化合作框架协议》对公司本年度及后续年度经营业绩 的影响需视协议双方后续实施情况而定。 3、公司最近三年披露的框架协议的情况详 ...

AI医疗概念盘初活跃 贝瑞基因涨停 智通财经4月11日电，早盘贝瑞基因涨停，泓博医药涨近15%，成都先导、塞力医疗、安必平、启迪药 业等跟涨。消息面上，美国食品药品管理局（FDA）宣称，将在单抗等诸多药物方面逐步放弃动物试验 路线，转而追求"更有效的人类相关研究方法"。 ...

成都市贝瑞和康基因技术股份有限公司主营业务为以高通量测序技术为基础的基因检测服务和基因检测 相关的设备、试剂销售。公司主要产品为基础科研服务、医学检测服务、试剂及仪器。公司是少数通 过"产品+服务"的综合方案为各级医院、第三方医学实验室等医疗机构提供医学产品及服务的公司之 一，凭借NIPT项目的先发优势，不断多元化基因检测服务项目并适时进行产品化，凭借在临床应用需 求的洞察力和在临床进行商业推广的成功经验，确立了公司在遗传学领域的领导地位。公司自主研发 的、具有万级技术分辨率的cSMART液态活检技术已获得国内外专利，凭借该技术优势，确立了公司在 肿瘤学领域的领先地位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)19贝瑞基因-14.71-9.712.2141.47亿行业平均 45.1547.514.67100.63亿行业中值28.6628.362.2442.39亿1硕世生物-1741.61-1741.611.0935.98亿2诺唯 赞-520.51-520.512.2588.50亿3博晖创新-332.64-204.803.6651.06亿4康泰医学-259.9030.492.6650.55亿5华 ...

3月31日，贝瑞基因今日收盘13.53元，下跌1.67%，最新市净率2.55，总市值47.83亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入8.23亿元，同比-4.96%；净利润1038.55万元，同 比107.70%，销售毛利率50.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)19贝瑞基因-16.97-11.202.5547.83亿行业平均 44.7248.614.80106.45亿行业中值32.5930.082.4746.64亿1硕世生物-1914.42-1914.421.2039.55亿2诺唯 赞-568.93-568.932.4696.73亿3博晖创新-292.72-180.233.2244.93亿4康泰医学-284.2833.352.9055.29亿5华 大基因-215.44235.662.23218.93亿6奥精医疗-118.65-118.651.5121.50亿7睿昂基因-81.14-81.141.2611.74亿 8华大智造-54.40-54.404.08325.92亿9中红医疗-52.39-35.640.8346.64亿10热景生物-49.28-49.282 ...